David Wirta
Research Subjects
David Wirta has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
David G. Evans
Total Eye Care, PA, Memphis, Tennessee
4 shared publicationsCarol Aune
2 shared publicationsEugene B. McLaurin
Total Eye Care, PA, Memphis, Tennessee
2 shared publicationsGary Jerkins
Advancing Vision Research, Goodlettsville, Tennessee
2 shared publicationsJames Paauw
Piedmont Eye Center, Lynchburg, Virginia
2 shared publications- Jason Bacharach
North Bay Eye Associates, Inc., Petaluma, USA
2 shared publications
Latest Publications
- Open Access
- 1 October 2025
- Published by Elsevier in Ophthalmology
- Vol. 133  (5) , 563-574
Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease
- 1 October 2025
- Published by Elsevier in Ophthalmology
- Vol. 133  (5) , 563-574
Open AccessAcoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease
- Open Access
- 16 September 2024
- Published by Elsevier in Ophthalmology
- Vol. 132  (1) , 79-91
Reversal of Pharmacologically Induced Mydriasis with Phentolamine Ophthalmic Solution
- 16 September 2024
- Published by Elsevier in Ophthalmology
- Vol. 132  (1) , 79-91
Open AccessReversal of Pharmacologically Induced Mydriasis with Phentolamine Ophthalmic Solution
- Open Access
- 21 May 2024
- Published by Wolters Kluwer Health in Cornea
- Vol. 44  (6) , 692-700
Long-Term Safety and Efficacy of a Water-Free Cyclosporine 0.1% Ophthalmic Solution for Treatment of Dry Eye Disease: ESSENCE-2 OLE
Purpose: The ESSENCE-2 Open-Label Extension study aimed to demonstrate long-term safety, tolerability, and efficacy of a novel water-free, nonpreserved topical cyclosporine 0.1% ophthalmic solution (US brand name VEVYE) for patients with dry eye disease (DED). Methods: This was a Phase 3, prospective, multicenter, open-label, clinical study. All patients received cyclosporine 0.1% ophthalmic solution and dosed each eye twice a day for 52 weeks. Primary safety end points were ocular and nonocular adverse events (AEs). Secondary safety end points included visual acuity, biomicroscopy, intraocular pressure, and dilated fundoscopy. Efficacy end points, such as total corneal fluorescein staining (tCFS) score (National Eye Institute [NEI] Scale), ocular symptoms (visual analog scale [VAS]), and Schirmer tear test, were also assessed. Results: A total of 202 patients were enrolled from the ESSENCE-2 study. At week 52, 175 patients (86.6%) completed ESSENCE-2 open-label extension. A total of 55 patients (27.5%) reported 74 ocular treatment-emergent adverse events (TEAEs). The most common ocular AE was instillation site pain (6.5%), which was of mild intensity in all cases. Patients showed statistically significant improvements in all prespecified efficacy end points compared with baseline at each visit. Corneal staining improvements were early and stabilized over time while tear production improved continuously. Symptomatology improvement followed these effects with scores reaching a minimum after 1 year of treatment. Conclusions: The water-free cyclosporine 0.1% ophthalmic solution was safe and well tolerated during long-term use. The results demonstrated sustained 1-year efficacy, in both signs and symptoms of DED, and may help understand short and long-term healing dynamics in a predominant inflammatory DED population.
- 21 May 2024
- Published by Wolters Kluwer Health in Cornea
- Vol. 44  (6) , 692-700
Open AccessLong-Term Safety and Efficacy of a Water-Free Cyclosporine 0.1% Ophthalmic Solution for Treatment of Dry Eye Disease: ESSENCE-2 OLE
Purpose: The ESSENCE-2 Open-Label Extension study aimed to demonstrate long-term safety, tolerability, and efficacy of a novel water-free, nonpreserved topical cyclosporine 0.1% ophthalmic solution (US brand name VEVYE) for patients with dry eye disease (DED). Methods: This was a Phase 3, prospective, multicenter, open-label, clinical study. All patients received cyclosporine 0.1% ophthalmic solution and dosed each eye twice a day for 52 weeks. Primary safety end points were ocular and nonocular adverse events (AEs). Secondary safety end points included visual acuity, biomicroscopy, intraocular pressure, and dilated fundoscopy. Efficacy end points, such as total corneal fluorescein staining (tCFS) score (National Eye Institute [NEI] Scale), ocular symptoms (visual analog scale [VAS]), and Schirmer tear test, were also assessed. Results: A total of 202 patients were enrolled from the ESSENCE-2 study. At week 52, 175 patients (86.6%) completed ESSENCE-2 open-label extension. A total of 55 patients (27.5%) reported 74 ocular treatment-emergent adverse events (TEAEs). The most common ocular AE was instillation site pain (6.5%), which was of mild intensity in all cases. Patients showed statistically significant improvements in all prespecified efficacy end points compared with baseline at each visit. Corneal staining improvements were early and stabilized over time while tear production improved continuously. Symptomatology improvement followed these effects with scores reaching a minimum after 1 year of treatment. Conclusions: The water-free cyclosporine 0.1% ophthalmic solution was safe and well tolerated during long-term use. The results demonstrated sustained 1-year efficacy, in both signs and symptoms of DED, and may help understand short and long-term healing dynamics in a predominant inflammatory DED population.
- Open Access
- 21 February 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 263, 23-34
Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)
- 21 February 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 263, 23-34
Open AccessOmidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)
- Top Cited PapersOpen Access
- 24 December 2022
- Published by Elsevier in Ophthalmology
- Vol. 130  (5) , 516-524
NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction
- 24 December 2022
- Published by Elsevier in Ophthalmology
- Vol. 130  (5) , 516-524
Top Cited PapersOpen AccessNOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction
- Open Access
- 12 August 2022
- Published by Elsevier in The Ocular Surface
- Vol. 26, 166-173
A randomized, vehicle-controlled, Phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1)
- 12 August 2022
- Published by Elsevier in The Ocular Surface
- Vol. 26, 166-173
Open AccessA randomized, vehicle-controlled, Phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1)
- Open Access
- 10 August 2022
- Published by Wolters Kluwer Health in Cornea
- Vol. 42  (4) , 435-443
Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1)
Purpose: The purpose of this study was to evaluate the safety and efficacy of lotilaner ophthalmic solution, 0.25%, compared with vehicle for the treatment of Demodex blepharitis. Methods: In this prospective, randomized, controlled, double-masked, phase 2b/3 clinical trial, 421 patients with Demodex blepharitis were randomly assigned in a 1:1 ratio to receive either lotilaner ophthalmic solution, 0.25% (study group), or vehicle without lotilaner (control group) bilaterally, twice daily for 43 days. Patients were evaluated at days 8, 15, 22, and 43. Outcome measures were complete collarette cure (collarette grade 0), clinically meaningful collarette cure (grade 0 or 1), mite eradication (0 mites/lash), erythema cure (grade 0), composite cure (grade 0 for collarettes/erythema), and drop comfort. Adverse events were also evaluated. Results: At day 43, the study group achieved a statistically significantly higher proportion of patients with clinically meaningful collarette cure (81.3% vs. 23.0%; P < 0.0001), complete collarette cure (44.0% vs. 7.4%; P < 0.0001), mite eradication (67.9% vs. 17.6%; P < 0.0001), erythema cure (19.1% vs. 6.9%; P = 0.0001), and composite cure (13.9% vs. 1.0%; P < 0.0001) than the control group. Nearly 92.0% of patients rated the study drop as neutral to very comfortable. All ocular adverse events in the study group were mild, with the most common being instillation site pain. Conclusions: Twice-daily treatment with a novel lotilaner ophthalmic solution, 0.25% for 43 days, is safe and effective for the treatment of Demodex blepharitis compared with the vehicle control.
- 10 August 2022
- Published by Wolters Kluwer Health in Cornea
- Vol. 42  (4) , 435-443
Open AccessLotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1)
Purpose: The purpose of this study was to evaluate the safety and efficacy of lotilaner ophthalmic solution, 0.25%, compared with vehicle for the treatment of Demodex blepharitis. Methods: In this prospective, randomized, controlled, double-masked, phase 2b/3 clinical trial, 421 patients with Demodex blepharitis were randomly assigned in a 1:1 ratio to receive either lotilaner ophthalmic solution, 0.25% (study group), or vehicle without lotilaner (control group) bilaterally, twice daily for 43 days. Patients were evaluated at days 8, 15, 22, and 43. Outcome measures were complete collarette cure (collarette grade 0), clinically meaningful collarette cure (grade 0 or 1), mite eradication (0 mites/lash), erythema cure (grade 0), composite cure (grade 0 for collarettes/erythema), and drop comfort. Adverse events were also evaluated. Results: At day 43, the study group achieved a statistically significantly higher proportion of patients with clinically meaningful collarette cure (81.3% vs. 23.0%; P < 0.0001), complete collarette cure (44.0% vs. 7.4%; P < 0.0001), mite eradication (67.9% vs. 17.6%; P < 0.0001), erythema cure (19.1% vs. 6.9%; P = 0.0001), and composite cure (13.9% vs. 1.0%; P < 0.0001) than the control group. Nearly 92.0% of patients rated the study drop as neutral to very comfortable. All ocular adverse events in the study group were mild, with the most common being instillation site pain. Conclusions: Twice-daily treatment with a novel lotilaner ophthalmic solution, 0.25% for 43 days, is safe and effective for the treatment of Demodex blepharitis compared with the vehicle control.
- 21 June 2022
- Published by American Medical Association (AMA) in JAMA
- Vol. 327  (23) , 2355-2356
Update on Dry Eye Disease
To the Editor The recent JAMA Insights article1 about the pathophysiology, diagnosis, and treatment of dry eye disease provided clear and concise information for practicing clinicians. However, other approaches for treatment of dry eye disease could have been mentioned, such as OC-01 (varenicline solution) nasal spray. In the primary phase 3 trial2 (ONSET-2) that included 758 patients with dry eye disease, treatment with OC-01 (varenicline solution) nasal spray for 4 weeks improved tear production and patient-reported symptoms compared with vehicle (control) nasal spray. In October 2021, this drug was approved by the US Food and Drug Administration for treatment of dry eye disease.
- 21 June 2022
- Published by American Medical Association (AMA) in JAMA
- Vol. 327  (23) , 2355-2356
Update on Dry Eye Disease
To the Editor The recent JAMA Insights article1 about the pathophysiology, diagnosis, and treatment of dry eye disease provided clear and concise information for practicing clinicians. However, other approaches for treatment of dry eye disease could have been mentioned, such as OC-01 (varenicline solution) nasal spray. In the primary phase 3 trial2 (ONSET-2) that included 758 patients with dry eye disease, treatment with OC-01 (varenicline solution) nasal spray for 4 weeks improved tear production and patient-reported symptoms compared with vehicle (control) nasal spray. In October 2021, this drug was approved by the US Food and Drug Administration for treatment of dry eye disease.
- Top Cited PapersOpen Access
- 1 April 2022
- Published by Elsevier in Ophthalmology
- Vol. 129  (4) , 379-387
Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease
- 1 April 2022
- Published by Elsevier in Ophthalmology
- Vol. 129  (4) , 379-387
Top Cited PapersOpen AccessEfficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease
- Open Access
- 21 December 2021
- Published by Wolters Kluwer Health in Cornea
- Vol. 41  (10) , 1207-1216
ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease
Purpose: The purpose of this trial was to evaluate the safety and efficacy of OC-01 (varenicline solution), a nicotinic acetylcholine receptor agonist nasal spray, on signs and symptoms of dry eye disease. Methods: A phase 2b, multicenter, randomized, double-masked, vehicle-controlled trial (ONSET-1; NCT03636061) was performed. Patients were aged 22 years or older with a physician's diagnosis of dry eye disease and previous use of artificial tears were randomized 1:1:1:1 to control (vehicle nasal spray twice daily [BID]), OC-01 0.006 mg BID, OC-01 0.03 mg BID, and OC-01 0.06 mg BID. The primary end point was the change in the anesthetized Schirmer test score from baseline to day 28 in the study eye. The secondary end points included the change in the eye dryness score from baseline to day 28. Results: One hundred eighty-two patients were randomized. After 28 days, patients who received OC-01 0.03 or 0.06 mg showed a statistically significant improvement in tear film production relative to vehicle, with least squares mean differences from vehicle of 7.7 mm [95% confidence interval, 3.8–11.7; P < 0.001] with OC-01 0.03 mg and 7.5 mm (95% confidence interval, 3.4–11.6; P < 0.001) with OC-01 0.06 mg. Patients receiving OC-01 0.03 mg showed a significant reduction in the eye dryness score by day 28 versus vehicle (P = 0.021); those receiving the OC-01 0.06 mg dose showed a nonsignificant reduction versus vehicle. OC-01 administration was associated with sneezing (62%–84%) and cough (9%–25%); these were transient and predominantly mild in severity. Conclusions: OC-01 nasal spray administered BID at 0.03 and 0.06 mg resulted in significant improvements in signs and symptoms of dry eye disease, was well tolerated, and warrants further clinical investigation.
- 21 December 2021
- Published by Wolters Kluwer Health in Cornea
- Vol. 41  (10) , 1207-1216
Open AccessONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease
Purpose: The purpose of this trial was to evaluate the safety and efficacy of OC-01 (varenicline solution), a nicotinic acetylcholine receptor agonist nasal spray, on signs and symptoms of dry eye disease. Methods: A phase 2b, multicenter, randomized, double-masked, vehicle-controlled trial (ONSET-1; NCT03636061) was performed. Patients were aged 22 years or older with a physician's diagnosis of dry eye disease and previous use of artificial tears were randomized 1:1:1:1 to control (vehicle nasal spray twice daily [BID]), OC-01 0.006 mg BID, OC-01 0.03 mg BID, and OC-01 0.06 mg BID. The primary end point was the change in the anesthetized Schirmer test score from baseline to day 28 in the study eye. The secondary end points included the change in the eye dryness score from baseline to day 28. Results: One hundred eighty-two patients were randomized. After 28 days, patients who received OC-01 0.03 or 0.06 mg showed a statistically significant improvement in tear film production relative to vehicle, with least squares mean differences from vehicle of 7.7 mm [95% confidence interval, 3.8–11.7; P < 0.001] with OC-01 0.03 mg and 7.5 mm (95% confidence interval, 3.4–11.6; P < 0.001) with OC-01 0.06 mg. Patients receiving OC-01 0.03 mg showed a significant reduction in the eye dryness score by day 28 versus vehicle (P = 0.021); those receiving the OC-01 0.06 mg dose showed a nonsignificant reduction versus vehicle. OC-01 administration was associated with sneezing (62%–84%) and cough (9%–25%); these were transient and predominantly mild in severity. Conclusions: OC-01 nasal spray administered BID at 0.03 and 0.06 mg resulted in significant improvements in signs and symptoms of dry eye disease, was well tolerated, and warrants further clinical investigation.